The IBMP is an independent research institute dedicated to the areas named in the institute's name.

Details about projects, symposia and reports in the media at https://www.medizin-nuernberg.de/ and in the curriculum vitae of the head of the institute.

Since 2012, we have been devoting the PEAK program with therapeutic drug monitoring (TDM) of antibiotics, antifungals and antivirals to the problem of multi-resistant germs in optimized, anti-infective therapy in intensive care units, which is carried out in close cooperation with clinics throughout Germany.

For more information on PEAK anti-infective monitoring, see also: www.medizin-nuernberg.de

Since the beginning of the corona crisis, we have established methods to measure the drugs in the body that are supposed to be effective against the SARS-CoV-2 virus, such as remdesivir, chloroquine, hydroxychloroquine and currently camostat. The list continues to grow.